A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

Longoni, Mattia; Bertini, Alessandro; Schifano, Nicolò; Zaffuto, Emanuele; Maggio, Paolo; Piercarlo, Rossi; Baldini, Sara; Carcano, Giulio; Antonini, Gabriele; Salonia, Andrea; Montorsi, Francesco; Dehò, Federico; Capogrosso, Paolo

doi:10.1080/14656566.2023.2221785

Cited by 2 publications

(1 citation statement)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…тадалафил избирательно и обратимо ингибирует циклическую гуанозинмонофосфат-специфическую фдэ-5, может помочь предотвратить систолическую Аг, её сердечно-сосудистые осложнения и снизить риск смерти [63]. ингибиторы фдэ-5 силденафил, варденафил, тадалафил и аванафил являются основными средствами лечения эд [64,65]. необходимо отметить, что концентрация этих препаратов в плазме может увеличиваться при одновременном применении с ингибиторами цитохрома Cyp3A, что будет способствовать повышению риска побочных эффектов [66].…”

Section: результатыunclassified

Sexual dysfunction in men and women with arterial hypertension

Kanorskii

2024

jour

View full text Add to dashboard Cite

Sexual dysfunction is often associated with hypertension but is not recognized, reported, or adequately treated. Research on sexual dysfunction is sparse, which may be due to the taboo nature of the topic. A literature search was conducted in five databases (PubMed, Web of Science, Scopus, Cochrane Library and PsycINFO) to identify articles published over the past ten years (from 2014 to 2024), using the keywords “sexual dysfunction”, “arterial” hypertension", "antihypertensive drugs", "erectile dysfunction". The review examines the prevalence, pathophysiology, clinical manifestations of sexual dysfunction in men and women, its relationship with arterial hypertension, antihypertensive therapy, concomitant pathology, and possible methods of correction.

show abstract

Section: результатыunclassified

Sexual dysfunction in men and women with arterial hypertension

Kanorskii

2024

jour

View full text Add to dashboard Cite

show abstract

The pathogenic role of the immune system in erectile dysfunction and Peyronie’s disease: focusing on immunopathophysiology and potential therapeutic strategies

Giagulli,

Lisco,

De Tullio

et al. 2024

Sexual Medicine Reviews

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) represents the major cause of male sexual dysfunction, which is often associated with obesity, diabetes mellitus, atherosclerotic cardiovascular disease, and cigarette smoking. Peyronie’s disease is a chronic disorder associated with irreversible fibrotic damage of the tunica albuginea leading to ED, painful erection, coital disturbance, and physical and social complaints. Both conditions are characterized by chronic inflammation, oxidative stress, and significant changes in intracavernous hydrodynamics. In this scenario, oxidized lipoproteins, M1-polarized macrophages, proinflammatory cytokines (such as the tumor necrosis factor α), endothelial nitric oxide synthase, penile smooth muscle cells, and toll-like receptors represent the main triggers of the inflammatory process in ED. Phosphodiesterase-5 inhibitors are the most common treatment for ED. This treatment is used intermittently, as it is conceived as a symptomatic and not curative therapy. Moreover, not all patients respond to phosphodiesterase-5 inhibitors (35%-85%), particularly those with dysmetabolic phenotypes. Additional or alternative treatments are therefore desirable, mostly in refractory cases. Objectives In this review, we describe the immune-mediated pathogenesis of ED and Peyronie’s disease (PD). In our literature search we placed particular emphasis on potentially practical therapeutic approaches, including natural products (such as polyphenols), due to their anti-inflammatory and antioxidant activities, stem cell therapy, and platelet-derived preparations. Methods We searched PubMed/MEDLINE, Web of Science, Scopus, Cochrane Library, Google Scholar, and institutional websites. Original studies, narrative reviews, systematic reviews, and meta-analyses written in English were searched, screened, and selected. Results In animal models of ED and PD, therapeutic approaches, including anti-inflammatory and antioxidant agents, stem cell therapy, and platelet-derived preparations, have provided positive results, including improved penile function, reduced inflammation and oxidative stress, and promotion of tissue repair. However, clinical evidence of improvement in human patients is still insufficient. Conclusion Promising results for treating ED and PD have been shown in preclinical and pilot clinical studies, but specific clinical trials are needed to validate the efficacy of these therapeutic approaches in men with ED.

show abstract

A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

Cited by 2 publications

References 116 publications

Sexual dysfunction in men and women with arterial hypertension

Sexual dysfunction in men and women with arterial hypertension

The pathogenic role of the immune system in erectile dysfunction and Peyronie’s disease: focusing on immunopathophysiology and potential therapeutic strategies

Contact Info

Product

Resources

About